The development of a vaccine to
bring toxoplasmosis under control has
been the aim of many investigators allover
the world. This study was designed
to test the effect of a new vaccine
derived from chemically modified
Toxoplasma antigen. There was direct
effect of the vaccine on fresh
Toxoplasma cyst wall. Stained blood
pictures of infected then vaccinated
mice (group III) showed 11000 immune
cells/ml, that was more than that
of vaccinated then infected mice in
group IV (5000 immune cells/ml). Humoral
immune response, determined
by measuring IgM titre was higher
also at group III (0.376 th 0.290) than at
group IV (0.283 th 0.082). This immune
response may be the cause of direct
stoppage of death rate of mice at group
III and long life to the end of the experiment
and shorter survival days for
mice at group IV. Lastly, these effects
were assured by histopathological
studies that showed repair of the
pathological changes caused by
Toxoplasma infection in group III after
vaccination. Results suggest a possible
curative effect with slight prophylactic
effect of that tested vaccine. |
